Additional Analyses
EVENT
The effects of biodegradable-polymer sirolimus-eluting stent or zotarolimus-eluting stent on the incidence of the primary outcome were consistent across prespecified subgroups (When the third universal MI definition was implemented in a prespecified analysis of the primary outcome, the event rates were 6.6% in the biodegradable-polymer sirolimus-eluting stent group and 6.3% in the zotarolimus-eluting stent group (risk difference, 0.3 percentage points; upper boundary of the 1-sided 95% CI, 2.2; upper boundary of the 1-sided 97.5% CI, 2.6; Time-to-event curves with landmark analysis at 30 days analyzed according to the Kaplan-Meier method are shown in 